Lexology August 4, 2020
Ropes & Gray LLP

Originally published on August 3, 2020 in Health Law360

This article is the first in a series to examine how the current wave of drug pricing reforms may affect drug companies’ business operations and, in particular, their compliance with existing federal price reporting and pricing requirements. It will examine the current bevy of federal administrative and legislative proposals in the context of existing federal law governing drug prices, with the aim of identifying the future and current effects that such proposals may hold for the drug industry. The second article will address the implications of state drug pricing initiatives, and the third article will explore enforcement of federal pricing requirements.

On July 24, President Trump announced a series of executive...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Insurance, Patient / Consumer, Pharma, Pharma / Biotech, Pricing / Spending, Provider
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Share This Article